Brought to you by 
Aspen takes an option to acquire 11 drugs from Merck for $600mm
18 Nov 2022
Executive Summary
South African pharmaceuticals company Aspen Pharmacare Holdings Ltd. is continuing on a 14-month long spending spree by taking an option to acquire 11 branded finished dosage form molecules from Merck Sharp & Dohme Ltd., the ex-US division of Merck & Co. Inc. The companies expect that Aspen will exercise the options by the end of 2013, at which point it would pay Merck $600mm.
Deal Industry
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Marketing (Licensing)
- Product Purchase
- Reverse Licensing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Aspen takes an option to acquire 11 drugs from Merck for $600mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice